Shukra Pharmaceuticals Reports Strong Profit Growth Amid Declining Net Sales in March 2025

Shukra Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, revealing a notable shift in its evaluation. The company's score has seen an adjustment, moving to a more favorable position compared to the previous three months. In terms of performance, Shukra Pharmaceuticals reported a profit before tax less other income (PBT) of Rs 6.10 crore, reflecting significant growth compared to the average of the previous four quarters. Similarly, the profit after tax (PAT) reached Rs 5.39 crore, also showing substantial growth against prior averages. The operating profit (PBDIT) was recorded at Rs 7.32 crore, marking the highest figure in the last five quarters, indicating a positive trend in operational efficiency. However, the company faced challenges with net sales, which totaled Rs 29.41 crore over the nine-month period, showing a decline year on year. This aspect highlights a contrasting trend in sales performance compared to the positive indicators in profitability. Overall, Shukra Pharmaceuticals' recent financial results illustrate a complex landscape of growth in profitability metrics alongside challenges in sales performance. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.